Compare CBIO & NATH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CBIO | NATH |
|---|---|---|
| Founded | 2003 | 1916 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Restaurants |
| Sector | | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 389.7M | 411.8M |
| IPO Year | N/A | 1996 |
| Metric | CBIO | NATH |
|---|---|---|
| Price | $12.02 | $100.65 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $26.67 | N/A |
| AVG Volume (30 Days) | ★ 163.9K | 38.2K |
| Earning Date | 01-01-0001 | 05-22-2026 |
| Dividend Yield | N/A | ★ 1.99% |
| EPS Growth | N/A | ★ 22.29 |
| EPS | N/A | ★ 4.17 |
| Revenue | N/A | ★ $104,201,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $24.07 |
| Revenue Growth | N/A | ★ 7.81 |
| 52 Week Low | $8.72 | $88.00 |
| 52 Week High | $17.39 | $118.32 |
| Indicator | CBIO | NATH |
|---|---|---|
| Relative Strength Index (RSI) | 56.70 | 55.05 |
| Support Level | $11.88 | $100.25 |
| Resistance Level | $13.37 | $101.71 |
| Average True Range (ATR) | 0.91 | 0.41 |
| MACD | 0.10 | -0.18 |
| Stochastic Oscillator | 53.37 | 50.00 |
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent believes CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. Crescent is advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.
Nathan's Famous Inc is an owner of fast food franchises in the United States. The company's reportable segment includes the Branded Product Program, Product licensing, Restaurant operations and Corporate. Branded Product Program derives revenue principally from the sale of hot dog products either directly to foodservice operators or to various foodservice distributors who resell the products to foodservice operators. It generates maximum revenue from the Branded Product Program segment. Geographically, it derives a majority of revenue from the United States.